Novanta’s (NASDAQ:NOVT) Q2 CY2026 Sales Top Estimates, Guides for Strong Full
Novanta (NASDAQ: NOVT) reported Q2 CY2026 revenue of $265.8 million, up 10.3% year on year and 1.3% above estimates, according to the company. Non-GAAP EPS was $0.89, up from $0.76 and 7.2% above consensus. It guided next-quarter revenue to $302 million (midpoint) and expects full-year EPS to rise from $3.48 to $3.94, per sell-side forecasts.
How this was made
The 30-second read
Why it matters
Q2 revenue and adjusted EPS beat, alongside stronger-than-expected next-quarter revenue guidance, are the key catalysts. However, operating margin fell sharply year over year, suggesting cost pressure that could limit sustained upside.
Market read
Traders can reassess near-term expectations for Novanta’s growth and profitability after the disclosed beat and upside revenue guidance, while monitoring whether margin pressure reverses.
What to watch
The article notes slowing annualized revenue growth over two years versus the five-year trend, so the guidance beat may not fully resolve longer-term deceleration concerns.
Background
Novanta is a medicine and manufacturing technology provider serving medical, life sciences, and manufacturing customers.
Ticker impact
Novanta reported Q2 CY2026 revenue of $265.8M (+10.3% YoY) and guided next-quarter revenue to $302M midpoint, above expectations.
Bias toward upward price pressure into the next earnings cycle, with follow-through dependent on whether margin compression reverses.
The article discloses specific Q2 results (revenue and adjusted EPS beats) plus a concrete next-quarter revenue midpoint that is stated to be above analyst expectations, which typically drives near-term repricing.
Market effects
Signals demand resilience in medical and manufacturing technology, but margin deterioration highlights execution risk for industrial tech peers.
Primarily US-listed industrials sentiment; limited direct regional spillover beyond US small/mid-cap tech/industrials.
Modest global read-through for medical/life-sciences instrumentation demand, without new international contract specifics.
Counterpoint
Margin compression (operating margin down to 6.8% from 11.4% YoY) could cap upside if expense growth persists despite revenue growth.
Key entities
- companyNovanta
NASDAQ-listed medicine and manufacturing technology provider reporting Q2 CY2026 results and next-quarter guidance.
